inhaled human insulin + glimepiride

A **combination drug** containing **inhaled human insulin** (such as used in Afrezza) and **glimepiride** (an oral sulfonylurea agent). Inhaled human insulin is a rapid-acting insulin administered via pulmonary inhalation, utilizing Technosphere technology for ultra-rapid systemic absorption and is indicated for prandial glucose control in diabetes mellitus[1][2][4]. Glimepiride is a sulfonylurea taken orally that stimulates the pancreas to increase endogenous insulin secretion[5]. Together, this combination may enhance glycemic control in patients with diabetes mellitus, especially type 2 diabetes, by providing both immediate exogenous insulin and endogenous insulin secretion mechanisms. Such a combination is not marketed under a unique brand name but may be explored in clinical use or research settings for intensified glucose management.